<p>加利福尼亚州诺瓦托，2025 年 12 月 19 日（GLOBE NEWSWIRE）——Ultragenyx Pharmaceutical Inc.（纳斯达克：RARE）是一家专注于开发和商业化稀有及超稀有疾病新疗法的生物制药公司，今天报告向九名新聘非执行官授予了 13,144 个公司普通股的限制性股票单位。这些奖励已获得公司董事会薪酬委员会的批准，并根据 Ultragenyx 就业诱导计划授予，授予日期为 2025 年 12 月 17 日，作为新员工入职 Ultragenyx 的诱导材料，符合纳斯达克上市规则 5635(c)(4)。</p>
<p>这些限制性股票单位在四年内逐步归属，授予日期每周年将有 25% 的基础股票归属，前提是员工在这些归属日期时持续受雇于公司。</p>
<p><strong>关于 Ultragenyx Pharmaceutical Inc.</strong></p>
<p>Ultragenyx 是一家生物制药公司，致力于为严重稀有和超稀有遗传疾病的患者提供新产品。公司建立了一个多样化的已批准疗法和产品候选组合，旨在解决具有高度未满足医疗需求和明确治疗生物学的疾病，这些疾病通常没有批准的疗法来治疗其根本病因。</p>
<p>公司由一支在稀有疾病治疗药物开发和商业化方面经验丰富的管理团队领导。Ultragenyx 的战略基于高效的药物开发，目标是以最大的紧迫感为患者提供安全有效的疗法。</p>
<p>有关 Ultragenyx 的更多信息，请访问公司网站：www.ultragenyx.com。</p>
<p>联系 Ultragenyx</p>
<p>投资者与媒体</p>
<p>Joshua Higa</p>
<p>(415) 475-6370</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05EZzJNQ00zTXpJNU9EQTRJekl3TURreU9URT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05EZzJNQ00zTXpJNU9EQTRJekl3TURreU9URT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NmM5YjAwZjAtMzBmNS00NGI5LThkMWYtZTNiMGJkMjQ1MWE1LTEwMjA4NjQtMjAyNS0xMi0xOS1lbg==/tiny/Ultragenyx-Pharmaceutical-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NmM5YjAwZjAtMzBmNS00NGI5LThkMWYtZTNiMGJkMjQ1MWE1LTEwMjA4NjQtMjAyNS0xMi0xOS1lbg==/tiny/Ultragenyx-Pharmaceutical-Inc-.png"/></p>

Ultragenyx制药

<p>Ultragenyx 制药公司宣布根据纳斯达克上市规则 5635(c)(4)，向九名新聘非执行官授予 13,144 个限制性股票单位，作为 Ultragenyx 就业诱导计划的一部分。这些股票单位将在四年内逐步归属，前提是持续就业。此举旨在吸引新员工加入公司</p>

<p>NOVATO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 13,144 restricted stock units of the company’s common stock to nine newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of December 17, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>加利福尼亚州诺瓦托，2025 年 12 月 19 日（GLOBE NEWSWIRE）——Ultragenyx Pharmaceutical Inc.（纳斯达克：RARE）是一家专注于开发和商业化稀有及超稀有疾病新疗法的生物制药公司，今天报告向九名新聘非执行官授予了 13,144 个公司普通股的限制性股票单位。这些奖励已获得公司董事会薪酬委员会的批准，并根据 Ultragenyx 就业诱导计划授予，授予日期为 2025 年 12 月 17 日，作为新员工入职 Ultragenyx 的诱导材料，符合纳斯达克上市规则 5635(c)(4)。</p>
</div><p>The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.</p>
<div class="lb-trans"><p>这些限制性股票单位在四年内逐步归属，授予日期每周年将有 25% 的基础股票归属，前提是员工在这些归属日期时持续受雇于公司。</p>
</div><p><strong>About Ultragenyx Pharmaceutical Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Ultragenyx Pharmaceutical Inc.</strong></p>
</div><p>Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.</p>
<div class="lb-trans"><p>Ultragenyx 是一家生物制药公司，致力于为严重稀有和超稀有遗传疾病的患者提供新产品。公司建立了一个多样化的已批准疗法和产品候选组合，旨在解决具有高度未满足医疗需求和明确治疗生物学的疾病，这些疾病通常没有批准的疗法来治疗其根本病因。</p>
</div><p>The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.</p>
<div class="lb-trans"><p>公司由一支在稀有疾病治疗药物开发和商业化方面经验丰富的管理团队领导。Ultragenyx 的战略基于高效的药物开发，目标是以最大的紧迫感为患者提供安全有效的疗法。</p>
</div><p>For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.</p>
<div class="lb-trans"><p>有关 Ultragenyx 的更多信息，请访问公司网站：www.ultragenyx.com。</p>
</div><p>Contact Ultragenyx</p>
<div class="lb-trans"><p>联系 Ultragenyx</p>
</div><p>Investors &amp; Media</p>
<div class="lb-trans"><p>投资者与媒体</p>
</div><p>Joshua Higa</p>
<div class="lb-trans"><p>Joshua Higa</p>
</div><p>(415) 475-6370</p>
<div class="lb-trans"><p>(415) 475-6370</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05EZzJNQ00zTXpJNU9EQTRJekl3TURreU9URT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwNDg2MCM3MzI5ODA4IzIwMDkyOTE="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NmM5YjAwZjAtMzBmNS00NGI5LThkMWYtZTNiMGJkMjQ1MWE1LTEwMjA4NjQtMjAyNS0xMi0xOS1lbg==/tiny/Ultragenyx-Pharmaceutical-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/NmM5YjAwZjAtMzBmNS00NGI5LThkMWYtZTNiMGJkMjQ1MWE1LTEwMjA4NjQtMjAyNS0xMi0xOS1lbg==/tiny/Ultragenyx-Pharmaceutical-Inc-.png"/></p>

Ultragenyx 报告根据纳斯达克上市规则 5635(c)(4) 授予的激励性授予 | RARE 股票新闻